Trial Profile
Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2021
Price :
$35
*
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda
- 30 Aug 2020 Primary endpoint (Percentage of Participants with Moderate or Severe Acute Gastroenteritis (AGE) Occur0ring 7 Days After Dosing Due to GI.1 or GII.4 NoV Strains (excluding Co-infection)) has not been met as per results published in the Vaccine
- 30 Aug 2020 Results published in the Vaccine
- 19 Jun 2018 Status changed from active, no longer recruiting to completed.